Ustekinumab Effective in TNFi-Refractory Crohn ' s Disease Ustekinumab Effective in TNFi-Refractory Crohn ' s Disease

Ustekinumab induced early response and sustained remission at 44 weeks significantly better than did placebo, with a similar side effect profile, three trials have found.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news